Heartseed株式会社 Logo

Heartseed株式会社

Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.

219A | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区芝浦1丁目2番3号シーバンスS館5階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Heartseed Inc. is a clinical-stage biotechnology company specializing in regenerative medicine for cardiac diseases. Founded in 2015 as a spin-off from Keio University, the company develops iPSC-derived cell therapies for severe heart failure. Its core strategy is "remuscularization," a novel approach to regenerate damaged heart tissue by transplanting highly purified cardiomyocyte spheroids. The lead pipeline product, HS-001, is an allogeneic iPSC-derived cardiomyocyte therapy administered via intramyocardial injection for patients with heart failure with reduced ejection fraction (HFrEF). Heartseed aims to provide a fundamental treatment for conditions where heart transplantation was previously the only curative option. The company also conducts research on next-generation therapies using autologous and HLA-edited iPSCs to minimize immune rejection.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Heartseed株式会社 and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-19 09:00
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2025-06-12 08:30
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-06-12 08:30
Interim Report
半期報告書-第10期(2024/11/01-2025/12/31)
Japanese 143.9 KB
2025-01-27 02:01
Regulatory News Service
臨時報告書
Japanese 21.3 KB
2025-01-27 02:01
Regulatory News Service
確認書
Japanese 8.0 KB
2025-01-27 02:00
Annual Report
有価証券報告書-第9期(2023/11/01-2024/10/31)
Japanese 6.0 MB
2025-01-27 02:00
Regulatory News Service
内部統制報告書-第9期(2023/11/01-2024/10/31)
Japanese 21.1 KB
2024-07-22 08:18
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 4.6 MB
2024-07-11 08:00
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 4.6 MB
2024-06-26 08:00
Prospectus
有価証券届出書(新規公開時)
Japanese 9.0 MB

Automate Your Workflow. Get a real-time feed of all Heartseed株式会社 filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Heartseed株式会社 via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
StemRIM Inc. Logo
Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.
Japan 4599
STENOCARE A/S Logo
Develops and distributes prescription medical cannabis oils in Northern Europe and Australia.
Denmark STENO
ST PHARM CO., LTD. Logo
A global CDMO specializing in APIs and RNA therapeutics for the gene therapy market.
South Korea 237690
Sugentech, Inc. Logo
Develops advanced in-vitro diagnostic systems for hospitals, clinics, and at-home use.
South Korea 253840
SUHEUNG CO.,LTD. Logo
Global manufacturer of capsules and contract manufacturing for pharma/nutraceutical industries.
South Korea 008490
Sumitomo Pharma Co., Ltd. Logo
R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.
Japan 4506
SunBio, Inc. Logo
Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.
South Korea 067370
Swedish Orphan Biovitrum Logo
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden SOBI
SymBio Pharmaceuticals Limited Logo
Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.
Japan 4582
SynAct Pharma Logo
Biotech developing oral therapies to resolve inflammation in diseases like rheumatoid arthritis.
Sweden SYNACT

Talk to a Data Expert

Have a question? We'll get back to you promptly.